Risk factor
Very high price volatility
Profitability factor
Undervalued vs peers
About
Arcturus Therapeutics Holdings Inc., an RNA medicines company, focuses on the development of vaccines for infectious, and liver and respiratory rare diseases in the United States. The company's development programs comprise LUNAR-OTC development program for ornithine transcarbamylase (OTC) deficiency; and LUNAR-CF program for cystic fibrosis lung disease caused by mutations in cystic fibrosis transmembrane conductance...
Company Valuation
From both historical and forecast perspectives, the stock is underpriced compared to similar stocks.
Target Price
The average target price of ARCT is 33 and suggests 364% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increas
Buy
Sell